

## Press release

August 1, 2024

### **BioSpring and Pantherna agree on strategic cooperation in the field of genome editing**

**Frankfurt am Main/Hennigsdorf, Germany.** BioSpring GmbH and Pantherna Therapeutics GmbH, two leading providers of therapeutic mRNA, have agreed on a strategic collaboration in the field of research and development and signed a cooperation agreement mid-July.

The focus of the collaboration targets further development and licensing of therapeutic mRNA molecules based on PTXmRNA® technology specifically for genome editing applications. BioSpring is the world's leading provider of RNA for genome editing applications. Pantherna specializes in the development of novel lipid nanoparticle (LNP) formulations (PTXΔLNP® technology) for the organ- and cell-selective uptake of therapeutically active mRNA (PTXmRNA®) for the effective expression of proteins in various diseases.

"With this research collaboration, we are combining the outstanding expertise of our companies in the field of therapeutic mRNA, creating synergies and thus developing the potential for innovative solutions for our clients," stated Dr Hüseyin Aygün, Chief Scientific Officer (CSO) and co-owner of BioSpring GmbH.

Dr Jörg Kaufmann, CSO of Pantherna Therapeutics GmbH, adds: "We are pleased to support Biospring and its customers seeking solutions for customized mRNA constructs and nucleic acid delivery systems in the field of genome editing with our mRNA-LNP expertise."

BioSpring and Pantherna have previously collaborated on joint projects. With this new collaboration, the companies are placing particular emphasis on utilizing mRNA technology within the rapidly expanding field of genome editing. The targeted modification of genes (or genome editing) holds the promise of effectively treating diseases or even completely curing them. In addition to rare diseases that have genetic causes, these can also include common diseases such as cardiovascular diseases, or cancer. The parties have agreed not to disclose the financial details of the collaboration.

**Contact**

BioSpring Gesellschaft für Biotechnologie mbH  
Dr. Martin Schink  
Alt-Fechenheim 34, 60386 Frankfurt am Main  
Phone: +49 (0) 69 66055000  
E-Mail: schink@biospring.de

**Contact**

Pantherna Therapeutics GmbH  
Dr. Ansgar Santel  
Neuendorfstrasse 20b, 16761 Hennigsdorf  
Phone: +49 (0) 3302 202 240 0  
E-Mail: a.santel@pantherna-therapeutics.com

**About BioSpring**

BioSpring is a contract manufacturer for the biotech and pharmaceutical industries and a global leader in the production and analysis of nucleic acids, which are used in medicine, diagnostics, bioanalytics and research. Oligonucleotides are made up of the same building blocks as human genetic material. BioSpring is the world's leading manufacturer of therapeutic gene scissors (genome editing) used in cell and gene therapy.

The active ingredients produced at BioSpring have the potential to enable therapies for a plethora of untreatable diseases. These include novel compounds for the treatment of cardiovascular, neurological, and metabolic diseases (and more), as well as cancer.

BioSpring was founded in Frankfurt am Main by Dr. Hüseyin Aygün and Dr. Sylvia Wojczewski, and is still owner-managed. The company, which now has over 650 employees, has its production headquarters in Frankfurt-Fechenheim, Germany, as well as a subsidiary in San Diego, USA, and, in the future, an additional 170,000 sqft production facility in Offenbach am Main, Germany, where up to 1,500 jobs will be created in the long term. Please find more information here [www.biospring.de](http://www.biospring.de)

**About Pantherna Therapeutics**

Pantherna Therapeutics GmbH develops novel first-in-class therapies based on mRNA for indications with high medical need. Pantherna's therapeutic programs are based on two innovative and proprietary platform technologies, the mRNA expression constructs (PTXmRNA®) and necessary lipid nanoparticles (PTXΔLNP®) for cell type-specific expression of therapeutic proteins. PAN004 is Pantherna's first development candidate to emerge from this platform and represents a defined mRNA-LNP formulation for the selective mRNA expression of a Tie2 agonist in the vascular endothelium of pulmonary capillaries. Pantherna is pursuing the development of a pipeline of novel mRNA-LNP candidates that will enable the therapeutic use of mRNA in various tissues and cell types. [www.pantherna-therapeutics.com](http://www.pantherna-therapeutics.com)